Cure8 research brief
The review suggests RDW, an inexpensive and widely available blood test parameter, is higher in IBD and correlates with disease activity—meaning it might help clinicians monitor disease alongside other tests.
If confirmed, RDW could offer a low-cost adjunct to existing inflammatory markers for people with Crohn’s disease or ulcerative colitis.
Clinicians (gastroenterologists, primary care), researchers studying IBD biomarkers, and adult patients interested in disease monitoring.
This systematic review and meta-analysis pooled studies on red blood cell distribution width (RDW) in inflammatory bowel disease (IBD).
The authors report that RDW is higher in people with IBD versus healthy controls and is associated with disease activity and severity; they also present pooled diagnostic performance metrics suggesting reasonably high sensitivity and specificity in some analyses.
RDW is a commonly reported parameter from routine complete blood counts, so if these findings are robust they suggest RDW could be a low-cost adjunctive biomarker to consider alongside established tests (CRP, fecal calprotectin) when assessing IBD activity. The paper emphasizes RDW’s availability and low cost as practical advantages.
This brief is grounded in the article abstract provided by the journal (structured content depth: abstract). It does not represent a full appraisal of individual study methods or risk of bias; the meta-analysis methods were described using PRISMA and random-effects models in the abstract.
Summary is grounded in the article abstract. RDW is a non-specific measure influenced by anemia and other conditions; the meta-analysis’ conclusions depend on included studies’ quality and heterogeneity. This is not a recommendation to change care without clinical context.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
